Schroder Investment Management Group
LXRX icon

Schroder Investment Management Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Schroder Investment Management Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-42,920
Closed -$618K – 1318
2017
Q1 		$618K Buy
+42,920
New +$637K ﹤0.01% 998
2015
Q2 		– Sell
-435,059
Closed -$2.9M – 1236
2015
Q1 		$2.9M Hold
435,059
– – 0.01% 818
2014
Q4 		$2.77M Hold
435,059
– – 0.01% 857
2014
Q3 		$4.29M Sell
435,059
-15,972
-4% -$171K 0.01% 802
2014
Q2 		$5.08M Sell
451,031
-11,983
-3% -$129K 0.01% 765
2014
Q1 		$5.61M Sell
463,014
-17,443
-4% -$223K 0.01% 747
2013
Q4 		$6.05M Sell
480,457
-48,672
-9% -$774K 0.01% 760
2013
Q3 		$8.82M Hold
529,129
– – 0.02% 657
2013
Q2 		$8.04M Buy
+529,129
New +$8.04M 0.02% 633

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Schroder Investment Management Group's LXRX Position: Q2 2017 in Review

Schroder Investment Management Group sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 42,920 shares — an estimated $618K sold.

Schroder Investment Management Group first reported a position in LXRX in Q2 2013 and held it in 9 quarters. The position peaked at $8.82M in Q3 2013. 136 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

  • Schroder Investment Management Group reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Schroder Investment Management Group sold 42,920 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $618K.
  • Schroder Investment Management Group first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Schroder Investment Management Group's Lexicon Pharmaceuticals position peaked at $8.82M in Q3 2013.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on Schroder Investment Management Group's 13F filing for Q2 2017, filed 10 Aug 2017.